Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week Low – Time to Sell?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) reached a new 52-week low during trading on Friday . The company traded as low as $8.97 and last traded at $9.01, with a volume of 512437 shares. The stock had previously closed at $9.46.

Analyst Ratings Changes

FOLD has been the topic of several analyst reports. Cantor Fitzgerald increased their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Guggenheim increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Bank of America lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Stock Down 5.8 %

The firm has a market cap of $2.66 billion, a P/E ratio of -26.21 and a beta of 0.62. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $9.95 and a 200-day moving average price of $10.55.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 22,901 shares of company stock worth $259,863 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $26,000. Hazlett Burt & Watson Inc. grew its holdings in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Blue Trust Inc. increased its position in shares of Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics in the 3rd quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics during the 3rd quarter worth about $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.